SHEET 1 OF												OF _ 1	
SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERC PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO. 6056-236				SERIAL NO. 09/485,323		
	INFOR	MATION DISC	URE CITA	NC						_			
MAY 1 2 2000 CC							APPLICANT: Stefan Niewiarowski et al.						
Bannan arte							FILING DATE February 7, GROUP 1651 2000						
U.S. PATENT DOCUMENTS													
EXAMINE R INITIAL	1	DOCUMENT NUMBER	DATE			NAME		CLASS	SUBC S	LAS	S FILING DATE (IF APPROPRIATE)		
27D	AA	5,318,899	06/07/94		Sc	Scarborough et al.		435	69.	6		***	
ags.	AB	5,510,332	04/23/96		Ko	Kogan et al.		514	14	14			
. *	AC										·		
	AD					<u> </u>	<u></u>						
FOREIGN PATENT DOCUMENTS													
4		DOCUMENT NO. DATE			COUNTRY		CLASS	SUBCLAS S		<u>RANSLATI</u> <u>ON</u> 'ES	NO		
<u> </u>	AE	WO 96/00581 01/11/9		6	6 PCT			<u> </u>					
	AF												
. AG													
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
200	AH	The Merck Index, Eighth Edition, Edited by P. Stecher et al., Rahway, NJ, Merck & Co., Inc., 1968, page 500.											
7	AI	Siigur et al., "cDNA Cloning and Deduced Amino Acid Sequence of Fibrinolytic Enzyme (Lebetase) from Vipera Lebetina Snake Venom. Biochemical and Biophysical Research Communications, 224(1): 229-336 (1996).											
·	AJ	Marchinkiewicz et al., "EC-3, A Novel MLD-Dependent Distintegrin From E. Carinatus Is A Potent Antagonist of α4 Integrins", Molecular Biology of the Cell Supp., Vol. 8, Abstract 1682 (Nov. 1997).											
	AK	Marcinkiewicz et al., "Isolation and characterization of two novel dimeric disintegrins: EC-3 and EMF-10 inhibiting interaction of lymphoid cells with VCAM-1", <u>Blood</u> , 90(10): 59b Suppl. 1, Abstract 2966 (Nov. 15, 1997)											
	AL			<u> </u>		<u>.</u>							
	AM								_	,			
examiner Leberal						DAT	E CONSIDERED			,	•	7	
EXAMINER line thro	: Init:	EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation											

if not in conformance and not considered. Include copy of this form with next communication to applicant.